Codexis (CDXS) Shares Outstanding (2010 - 2026)
Codexis (CDXS) posted quarterly Shares Outstanding (Entity) of $90.9 million for Q1 2026, up 9.72% year-over-year from $82.8 million in Q1 2025, and little changed quarter-over-quarter from $90.5 million in Q4 2025.
Codexis (CDXS) Shares Outstanding (2010 - 2026) Analysis & Trends
Codexis' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $90.9 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 9.72% year-over-year to $90.9 million; the TTM figure through Mar 2026 stood at $90.9 million (up 9.72% YoY), while the FY2025 annual figure was $90.5 million, up 10.54% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $90.9 million, roughly flat from $90.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $90.9 million in Q1 2026, with the low at $65.3 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $70.6 million (2024), against an average of $75.8 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) increased 1.08% in 2022, then rose 27.27% in 2025.
- Codexis' Shares Outstanding (Entity) stood at $65.8 million in 2022, then gained by 6.22% to $69.9 million in 2023, then increased by 17.09% to $81.8 million in 2024, then gained by 10.54% to $90.5 million in 2025, then rose by 0.46% to $90.9 million in 2026.
- Business Quant data shows CDXS's Shares Outstanding (Entity) at $90.9 million in Q1 2026, $90.5 million in Q4 2025, and $90.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | 91.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.05 Mn |
| Mar 31, 2026 | 90.77 Mn |
| Dec 31, 2025 | 87.14 Mn |
| Sep 30, 2025 | 90.25 Mn |
| Jun 30, 2025 | 85.39 Mn |
| Mar 31, 2025 | 82.41 Mn |
| Dec 31, 2024 | 73.41 Mn |
| Sep 30, 2024 | 72.03 Mn |
| Jun 30, 2024 | 70.38 Mn |
| Mar 31, 2024 | 69.85 Mn |
| Dec 31, 2023 | 68.13 Mn |
| Sep 30, 2023 | 69.47 Mn |
| Jun 30, 2023 | 67.57 Mn |
| Mar 31, 2023 | 65.93 Mn |
| Dec 31, 2022 | 65.34 Mn |
| Sep 30, 2022 | 65.43 Mn |
| Jun 30, 2022 | 65.29 Mn |
| Mar 31, 2022 | 65.10 Mn |
| Dec 31, 2021 | 64.57 Mn |
| Sep 30, 2021 | 64.63 Mn |